Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.23 · Revenue $137.31M · 2 analysts
Est. EPS $-0.17 · Revenue $153.23M · 2 analysts
Est. EPS $-0.65 · Revenue $605.39M · 2 analysts
Est. EPS $0.02 · Revenue $175.90M · 1 analysts
EPS €-0.13 · Revenue €145.85M
EPS €-0.35 · Revenue €159.22M
EPS €-0.28 · Revenue €757.26M
EPS €-0.12 · Revenue €163.89M
EPS €-0.12 · Revenue €171.24M
EPS €-0.09 · Revenue €199.98M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $757.3M | -5.0% | -8.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-99.4M | +49.3% | +61.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +8.3% | -42.6% | -10.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -17.9% | +0.1% | -0.7% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -13.1% | +46.6% | +58.2% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-78.7M | +30.9% | -1764.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -10.4% | +27.3% | -1935.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 55.0% | +18.2% | +29.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.07x | +4.7% | +38.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.8B | -7.0% | -4.1% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.28 vs -0.21 | -33.2% | -0.13 vs -0.03 | -271.9% |
| Revenue Surprise | $757.3M vs $777.8M | -2.6% | $145.9M vs $143.5M | +1.6% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Oct 22, 2018 | Anderson Mark Monroe | director | Stock Option (right to buy) | A | 100,000 | $2.50 |
| Oct 22, 2018 | Anderson Mark Monroe | director: | — | — | 0 | — |
| Oct 1, 2018 | QUINTON KEITH | — | — | — | 0 | — |
| Oct 1, 2018 | Smith Marcus L. | — | — | — | 0 | — |
| Aug 13, 2018 | Smith Scott Clifford | director | Stock Option (right to buy) | A | 100,000 | $2.50 |
Operator : Ladies and gentlemen, welcome to the Evotec preliminary second quarter and first half 2026 results and update full year 2026 outlook. I am Moritz, your Chorus Call operator. I would like to remind you that all participants will be in the listen-only mode and the conference is being recorded. The presentation will be followed by a question and answer session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it is my pleasure to hand over to Sarah Fakih, Head of Global Communications and Investor Relations. Please go ahead. Sarah Fakih : Thank you, Moritz. Good morning. Good afternoon, and welcome to today's webcast and conference call. My name is Sarah Fakih, and I am the Head of Global Communications and Investor Relations at Evotec. Please allow me to introduce today's speakers. Joining me on the call are Christian Wojczewski, Chief Executive Officer of Evotec, and Claire Hinshelwood, our Chief Financial Officer. Please note that this call is being webcast live and will be archived in the events calendar on our website. Before we begin, a few forward-looking statements. The discussion and responses to your questions on this call reflect management's views as of today, Tuesday, July 14th, 2026. During this call, we will make statements and provide responses that state our intentions, beliefs, expectations, or projections regarding the future. These statements constitute forward-looking statements within the meaning of applicable securities laws. They are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied. Evotec disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. For further information regarding these risks and uncertainties, please refer to our public filings and disclosures. With this, let me hand over the call to Christian. Christian Wojczewski : Thank you, Sarah. Good morning and good afternoon to everyone. Thank you for joining today's call. Following our announcement last night, we are providing today an update based on preliminary unaudited financial results for the second quarter and first half of 2026, as well as an updated outlook for the full year. As a reminder, publication of our full financial results is scheduled for August 13th. During our full year 2025 results presentation in April, we guided for a challenging first half of 2026. This outlook primarily reflected our anticipated continuation of the softness in the early drug discovery market seen in 2025, as well as the effect of the non-recurrence of the $25 million Sandoz licensing payment in the first quarter of the previous year. Our preliminary second quarter results extend the trends we saw in the first quarter. Group revenues in the first half of 2026 …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Christian Wojczewski | CEO & Chairperson of the Management Board | EUR 2,916,240 | — | 1973 | Active |
Claire Hinshelwood | Chief Financial Officer & Member of Management Board | EUR 1,338,986 | Female | — | Active |
Aurelie Dalbiez | Chief People Officer & Member of Management Board | EUR 1,118,398 | Female | 1977 | Active |
Cord Dohrmann | Chief Scientific Officer & Member of Management Board | EUR 890,749 | — | 1964 | Active |
Ingrid Mller | Chief Operating Officer & Member of Management Board | EUR 673,657 | — | 1972 | Active |
Ian Hunneyball | Senior Vice President of Programme Management & Clinical Operations | EUR 135,422 | — | 1950 | Active |
Sarah Fakih | Executive VP, Head of Global Communications & Investor Relations | — | — | — | Active |
Uwe Andag | EVP Head of Metabolic Diseases | — | — | — | Active |
David Hallet | Executive Vice President | — | — | — | Active |
Christian Dargel | EVice President Global Head of Legal & Compliance | — | — | 1971 | Active |
Evotec AG (NASDAQ: EVO - Get Free Report) has been given a consensus recommendation of "Hold" by the five analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company.
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases PR Newswire
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need HAMBURG, Germany, Aug. 6, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets.
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N.
PALO ALTO, Calif.--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independentl.
